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Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) in ﬁrst complete remission is a standard of care for adult patients
with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the
stratiﬁcation systems vary among study groups. Inadequate response at the level of minimal residual disease is the most
commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group
for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and
Marrow Transplantation, we summarize available evidence and reﬂect current clinical practice in major European study groups
regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells
and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.
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Allogeneic (allo) hematopoietic stem cell transplantation
(HSCT) is considered an effective treatment for preventing
relapse in patients with Philadelphia chromosome (Ph)-nega-
tive acute lymphoblastic leukemia (ALL), combining myeloa-
blative doses of chemotherapy and/or radiotherapy with
potential beneﬁcial graft-versus-leukemia reaction mediated by
T cells of donor origin. Unfortunately, it is also associated with
signiﬁcant incidence of non-relapse mortality (NRM), reaching
15% after alloHSCT from matched sibling donors (MSD) and
22% for HSCT from unrelated donors (URD) [1]. Therefore,
the use of alloHSCT is weighed against the reduction of the
risk of relapse and the risk of NRM. However, despite attempts
to elaborate prognostic scores, the estimation of these measures
is uneasy and therefore potential beneﬁt from alloHSCT in
many individual cases is uncertain [2, 3].
Furthermore, all prospective studies evaluating the role of
alloHSCT for adults with ALL have been conducted con-
sidering the availability of human leukocyte antigen (HLA)
identical MSD, while the majority of alloHSCTs nowadays are
preformed using URD [4]. Moreover, in recent years, the
number of HSCTs from mismatched related donors (MMRD),
mostly haploidentical donors have been growing [5]. In addi-
tion, the use of transplantations with reduced intensity con-
ditioning (RIC) allowed for wider application of alloHSCT to
patients at older age and those with comorbidities. In contrast,
the use of autologous (auto)HSCT decreased over time due to
negative results of some prospective trials; however, with strict
monitoring of MRD it is conceivable that some patient popu-
lations may beneﬁt from this treatment option [6].
Altogether, the role of both alloHSCT and autoHSCT for
adults with Ph-negative ALL requires re-evaluation. In view
of lack of prospective, randomized studies addressing this
issue in the modern era, detailed indications for HSCT are
based mainly on expert opinions and vary among countries.
The goal of the current review was to summarize available
evidence and reﬂect current clinical practice in major Eur-
opean study groups. Furthermore, we were able to establish a
position statement elaborated by leading investigators repre-
senting the European Working Group for Adult Acute
Lymphoblastic Leukemia (EWALL) and experts from the
Acute Leukemia Working Party (ALWP) of the European
Society for Blood and Marrow Transplantation (EBMT).
Prospective studies on the role of HSCT in
adults with ALL
Before the era of routine MRD assessment
In the 1980s and 1990s, several prospective studies have
been conducted based on genetic randomization. Patients
in ﬁrst complete remission (CR1) having MSD were
offered alloHSCT, while those lacking MSD were treated
with either autoHSCT or conventional-dose maintenance
chemotherapy.
In three studies (Bordeaux-Grenoble-Marseille-Toulouse
study, GOELAL02 trial, HOVON-18/37 trial) alloHSCT
was compared with autoHSCT [7–9]. All of them demon-
strated superiority of allogeneic transplantation in terms of
leukemia-free survival (LFS).
In a LALA-87 study, patients who achieved CR and had
MSD were assigned to allograft, whereas those without a
donor were randomized to receive either autoHSCT or
conventional-dose chemotherapy [10]. Intention-to-treat
analysis showed increased overall survival (OS) for
patients having a donor (46% vs. 31% at 10 years, p=
0.04). The advantage was signiﬁcant for high-risk (p=
0.009) but not for standard-risk ALL (p= 0.06). In a fol-
lowing LALA-94 trial, a similar design was applied for
patients with high-risk ALL [11]. In both Ph-negative and
Ph-positive groups, having a donor was associated with
signiﬁcantly increased probability of 3-year LFS. No
advantage of autoHSCT over chemotherapy could be
demonstrated.
Another two studies comparing MSD-HSCT, autoHSCT
and conventional-dose chemotherapy as a post-
consolidation treatment of adults with high-risk ALL were
performed by the PETHEMA and EORTC groups, respec-
tively [12, 13]. In these studies, however, no signiﬁcant
differences between study arms could be demonstrated.
The Medical Research Council (MRC) UKALL XII/
ECOG 2993 was the largest study based on “genetic” ran-
domization, including 1646 adults with both standard- and
high-risk ALL [14]. Patients received two phases of
induction and, if in remission, were assigned to alloHSCT if
they had MSD. Remaining patients were randomized to
chemotherapy for 2.5 years or autoHSCT. A donor versus
no-donor analysis restricted to patients with Ph-negative
ALL showed superiority of alloHSCT (OS, 53% versus
45% at 5 years, p= 0.01). The survival difference was
signiﬁcant in standard-risk but not in high-risk patients
due to a high NRM (36% at 2 years) in the latter group.
Patients randomized to chemotherapy had a higher 5-year
OS rate than those assigned to autoHSCT (46% vs. 37%,
p= 0.03).
Taken together, results of the above cited studies pro-
vided rationale to use alloHSCT as a tool to prevent relapse
in adults with ALL in CR1. However, identiﬁcation of
patients who most likely beneﬁt from alloHSCT or in
whom this treatment option could be avoided remained
uncertain. Furthermore, it has been demonstrated that
autoHSCT is inferior to conventional-dose consolidation,
and its use after consolidation does not provide substantial
beneﬁt.
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In the era of routine MRD assessment
Several methods have been elaborated to assess MRD in
adults with ALL [15]. For patients with Ph-positive ALL,
detection of BCR-ABL transcript by real-time quantitative
polymerase chain reaction (PCR) is preferred. In Ph-
negative ALL, MRD may be assessed either by detection
of leukemia-speciﬁc phenotype using multiparameter ﬂow
cytometry or clonally rearranged genes encoding for
immunoglobulin/T-cell receptor chains by PCR. Sensitivity
of PCR-based methods is higher compared to ﬂow cyto-
metry; however, both were found feasible in clinical routine
with high concordance of the results [16]. MRD positivity
was demonstrated to be the most important prognostic
factor for relapse in ALL. Its effect is independent from the
presence of conventional risk factors. In the PALG 4-2002
study, a multivariate analysis revealed that only MRD level
>10−3 after induction (hazard ratio (HR)= 3.07, p=
0.0002), age >35 years (HR= 2.36, p= 0.009) and initial
leukocyte count >30 × 109/L (HR= 1.85, p= 0.04) sig-
niﬁcantly inﬂuenced the risk of relapse [17]. In a pooled
analysis from the GMALL 06/99 and 07/03 trials, the per-
sistence of MRD after induction and/or consolidation was
associated with signiﬁcantly shorter duration of CR. The
difference was particularly distinct among patients who
were not treated with alloHSCT [18]. In another GMALL
study focused on patients with standard-risk ALL, who
completed 1 year of chemotherapy, detection of MRD fol-
lowing previous MRD-negative status was associated with
61% relapse rate compared to only 6% in patients with
continuous MRD negativity [19]. Therefore, both inade-
quate early response and late MRD appearance should be
considered for risk stratiﬁcation.
Bassan et al. [20] published the ﬁrst prospective study, in
which MRD status was taken into account for decisions
regarding alloHSCT. MRD was tested at weeks 10, 16 and
22 using real-time quantitative PCR with one or more
sensitive probes. Only patients with t(9;22) or MLL rear-
rangement were immediately eligible for alloHSCT. Among
remaining patients those with negative or low positive
(<10−4) PCR signal at week 16 and totally undetectable
signal at week 22 were treated with maintenance che-
motherapy. Patients not fulﬁlling the above criterion were
candidates for alloHSCT. MRD positivity was detected in
54 out of 112 evaluable patients among whom 36 (67%)
individuals were actually treated with alloHSCT. MRD
level was found to be the most important prognostic factor
for LFS (72% vs. 14% at 5 years, p= 0.001). Among
MRD-negative patients, the LFS rates were independent of
the presence of conventional risk factors. Therefore, the
authors concluded that MRD analysis during early post-
remission therapy improves risk categorizations and rein-
forces risk-oriented strategies.
In the PETHEMA ALL-AR03 trial, patients with high-risk
Ph-negative ALL showing good early morphological response
(<10% blasts in bone marrow at day 14 of induction) and
MRD level assessed by ﬂow cytometry less than 5 × 10−4 at
the end of consolidation were assigned to delayed consolida-
tion and maintenance chemotherapy [21]. AlloHSCT was
scheduled only in patients with poor early morphological
response or MRD level ≥5 × 10−4, and was actually performed
in 50 out of 71 assigned individuals. The probability of LFS at
5 years for respective cohorts was 55 and 32% (p= 0.002),
respectively. However, in the analysis restricted to patients with
“stringent” high-risk features, i.e., high initial leukocyte count,
unfavorable immunophenotype or adverse karyotype, the dif-
ference was no longer statistically signiﬁcant (52% vs. 38%,
p= 0.11), suggesting that the use of alloHSCT may partially
overcome negative prognostic impact of MRD positivity.
In two subsequent trials (GRALL-2003 and GRALL-
2005) by the French/Belgium/Swiss group, 522 Ph-negative
ALL patients up to the age of 55 years, with high-risk
features, as assessed based on conventional criteria, were
intended for alloHSCT from either MSD or URD [22].
Among these, 282 (54%) actually received a transplant in
CR1. Induction and consolidation regimens were intensiﬁed
following the pediatric protocols. MRD was monitored by
PCR after the ﬁrst course of induction and after three blocks
of consolidation. In a time-dependent analysis, the authors
examined post hoc the impact of alloHSCT on the overall
outcome. AlloHSCT was associated with longer LFS in
patients with post-induction MRD ≥10−3 (HR= 0.40,
p= 0.001) but not in good MRD responders.
Subsequently, results of MRD assessment have been
incorporated in stratiﬁcation systems of Ph-negative ALL by
many study groups. It may be used to identify patients who
require alloHSCT despite lack of other high-risk features as
well as those patients in whom alloHSCT may be avoided
despite belonging to the high-risk group. However, the strate-
gies may depend on the speciﬁc chemotherapy protocols and
sensitivity of MRD techniques. It should be emphasized that
chemotherapy backbone in most of above cited studies was
very intensive, and pediatric inspired. These protocols may
produce high cure rate even without alloHSCT [23]. In many
countries, however, this is not routine and less intensive regi-
mens, e.g., hyperCVAD (fractionated cyclophosphamide, vin-
cristin, doxorubicin, dexamethasone), are commonly used
across the world. In such a case the relevance of MRD nega-
tivity may not necessarily be as strong as in pediatric-like
protocols and the indications for alloHSCT should be probably
based on conventional risk factors in addition to MRD status.
Similar dilemma is regarding patients who cannot tolerate
intensive chemotherapy and require dose reductions and treat-
ment delays. Finally, following results of the MRC UKALL
XII/ECOG 2993 study, even standard-risk patients having
MSD may be considered candidates for alloHSCT [14].
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According to a retrospective, single-center analysis from
Duarte (CA, USA), cytogenetics does not impact on out-
come of adults with ALL [24]. In recent years, however,
some new molecular subtypes have been identiﬁed,
including Ph-like ALL, characterized by gene expression
proﬁle similar to Ph-positive ALL in the absence of BCR/
ABL1 rearrangement. It is associated with poor prognosis in
both children and adults [25, 26]. According to small data
reported by Jain et al. [26], achieving MRD negativity does
not change inferior long-term outcomes in this setting.
There is lack of data of whether alloHSCT is superior to
pediatric-inspired regimens for Ph-like ALL. Prospective
studies are needed to deﬁne if all these patients should be
treated with alloHSCT regardless of the MRD status.
Similar dilemmas regard early thymic precursor (ETP)
ALL which is a high-risk subgroup of T-lineage ALL char-
acterized by speciﬁc stem cell and myeloid features [27].
According to the analysis by the French group, including
47 adults with ETP-ALL, the rate of MRD positivity after
induction was signiﬁcantly higher compared to other patients
with T-cell ALL [28]. However, the use of alloHSCT was
associated with marked improvement of results leading to
comparable outcomes. The authors suggested that the use of
response-based risk stratiﬁcation and therapy intensiﬁcation
abrogates the poor prognosis of adult ETP-ALL and that there
is no need to elaborate strategies speciﬁc for this subtype. On
the other hand, in another study by the French group focused
on T-cell ALL, some molecular features were shown to have
strong impact on outcome independently of the MRD status
[29]. High-risk molecular subgroup was deﬁned as: no
NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or
PTEN gene alteration. These patients as well as those with
complex karyotype (≥5 abnormalities) are postulated to be
candidates for alloHSCT [29, 30].
Transplant options for adults with ALL
Types of donor
Several donor types may be considered for adults with
ALL. Initially MSDs predominated, but with increasing
number of unrelated volunteers, URD-HSCT became the
most popular option. According to a recent EBMT report
focused on adults with ALL, between years 2010 and 2012,
transplantations from unrelated donors accounted for 52%
of all procedures, followed by MSD-HSCT (37%), MMRD-
HSCT (5%) and autoHSCT (6%) [31].
Several reports suggested that results of MSD-HSCT and
URD-HSCT for patients with ALL may be comparable. In an
analysis by Tomblyn et al. [32], the use of well-matched or
partially matched URD was not associated with inferior out-
come compared to MSD. In a Japanese study the OS rates after
URD-HCT and MSD-HCT for ALL patients in CR1 were
superimposable; however, HLA disparities were associated
with increased risk of NRM [33]. According to a recent ana-
lysis by the EBMT, results of alloHSCT for adults with ALL in
CR1 improved signiﬁcantly over time with 2-year LFS rates
reaching 60% for both MSD- and URD-HSCTs performed
between years 2008 and 2012 [1]. However, in a multivariate
model, the use of URD was associated with signiﬁcantly
increased risk on NRM (HR= 2.11, p= 0.002) and overall
mortality (HR= 1.52, p= 0.01). In that study, 29% of URD-
HSCTs were performed across single (22%) or double (7%)
HLA antigen or allele mismatches.
MSD and matched URD are considered preferable options
for ALL patients in need of alloHSCT. However, a signiﬁcant
proportion of ALL patients still lack HLA-compatible donor
and therefore require alternative approaches. In such a case
either mismatched URD, MMRD or unrelated cord blood may
be considered. In recent years, family haploidentical donors,
who may include either children, parents or the majority of
siblings, have become more and more practiced following the
introduction of new immunosuppressive protocols based on
post-transplant use of cyclophosphamide, allowing for unma-
nipulated graft without ex vivo T-cell depletion [5, 34].
According to a recent analysis by the EBMT, including 91
patients with ALL in CR1, the probability of LFS at 3 years
after unmanipulated MMRD-HSCT was 47% [35]. Similar
results (52% LFS rate) were reported by Srour et al. [36].
Unrelated cord blood transplantation (UCBT) is another
alternative option for ALL patients lacking MSD. The
report by Marks et al. [37] comparing UCBT and URD-
HSCT showed equivalent adjusted survival. Similarly, in a
recent study by the Japanese group, no signiﬁcant differ-
ences could be demonstrated for adult patients with ALL
treated with either UCBT, 8/8 matched URD bone marrow
transplantation or 7/8 matched unrelated donor transplan-
tation [38]. However, in contrast to MMRD-HSCT, the
application of UCBT in Europe tends to decrease, probably
due to the high cost of the procedure [5].
Considering all alternative donor options, it may be stated
that in the modern era all ALL patients being in need of
alloHSCT may be offered such treatment. On the other hand,
further comparative, large-scale analyses are needed to esti-
mate risks and beneﬁts associated with particular procedures.
In contrast to alloHSCT, the role of autoHSCT for
patients with Ph-negative ALL appears questionable and the
number of procedures is decreasing [31]. The outcome of
autoHSCT is mainly affected by the MRD status at the time
of transplantation [6].
Conditioning
Total body irradiation (TBI) is considered a standard backbone
for myeloablative conditioning in adults with ALL. Although it
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has never been prospectively evaluated, results of numerous
retrospective analyses indicated its advantage over
chemotherapy-based regimens mainly thanks to reduced risk of
relapse (HR= 0.48, p= 0.004, according to recent analysis by
the EBMT) [1, 39–41]. It must be stressed, however, that TBI
methods are very heterogeneous in terms of the dosage, timing
and many technical aspects, and therefore insufﬁciently stan-
dardized at the international level [42]. As well, the optimal
chemotherapy counterpart of TBI has not been deﬁned, so far.
The most practiced regimen includes 12 Gy TBI applied
in 6 fractions in combination with cyclophosphamide (Cy)
at the total dose of 120 mg/kg. However, some retrospective
analyses suggested that the combination with etoposide may
be more effective, especially for patients transplanted in
CR2 [43, 44]. Furthermore, according to the study by Marks
et al. [43], patients treated with alloHSCT in CR2 beneﬁted
from TBI dose ≥13 Gy as compared to <13 Gy, in terms of
reduced risk of relapse and improved LFS. The Japanese
group performed a retrospective study comparing 1178
ALL patients treated in ﬁrst or subsequent CR with Cy/TBI
and 376 ALL patients receiving Cy/TBI in combination
with intermediate doses of etoposide (VP16, 30–40 mg/kg)
[45]. The latter was associated with decreased risk of
relapse (HR= 0.75, p= 0.05) and improved LFS (HR=
0.76, p= 0.01). According to the study by the EBMT the
number of TBI fractions may be safely reduced to 3 or 4,
which makes the application of TBI easier from the logis-
tical point of view [46].
The use of TBI may be associated with increased risk of
late adverse effects, including secondary solid tumors [47].
Hence, attempts to substitute it by introducing novel
chemotherapy-based protocols have been done. According to
a retrospective analysis by Mitsuhashi et al. [48], the use of
intravenous (i.v.) instead of oral busulfan in combination with
cyclophosphamide may be associated with results comparable
to TBI [48]. However, the number of patients treated with i.v.
busulfan was relatively small (n= 40). Kebriaei et al. [49]
compared results of 819 patients who received TBI combined
with etoposide or cyclophosphamide and 299 patients treated
with i.v. busulfan combined with either cyclophosphamide,
melphalan, ﬂudarabine or clofarabine [49]. In a multivariate
model the use of busulfan was associated with a signiﬁcantly
higher risk of relapse (HR= 1.46, p= 0.002) but similar
NRM, LFS and OS. The authors concluded that i.v. busulfan-
based conditioning is a valuable option for patients who
cannot tolerate TBI [49]. Alternative approaches include the
use of regimens based on high doses of thiotepa. Thiotepa
penetrates the blood–brain barrier which may be important for
preventing relapses in central nervous system. Initial reports,
including retrospective analysis by the EBMT, show
encouraging results [50]. Further studies are needed to con-
ﬁrm non-inferiority of thiotepa- compared to TBI-based
regimens.
The introduction of RIC or non-myeloablative regi-
mens allowed for wider application of alloHSCT to older
patients with ALL as well as to those with signiﬁcant
comorbidities. Although the role of RIC-alloHSCT for
older adults with ALL has never been prospectively
evaluated, data from retrospective reports are encoura-
ging. According to recent analysis by the Center for
International Blood and Marrow Transplant Research
(CIBMTR), evaluating 273 ALL patients aged 55 years or
older with B-cell ALL, including 50% with Ph-positive
disease, the probability of OS at 3 years was 45%, pro-
vided that the transplantation was performed in CR1 [51].
In contrast to myeloablative preparative regimens, the
RIC ones are more frequently based on chemotherapy
than irradiation [31]. The spectrum of RICs is very wide
and data comparing particular regimens for adults with
ALL are pending. In a prospective UK NCRI
UKALL14 study, 186 patients aged 40 years or older were
treated with RIC-alloHSCT in ﬁrst CR [52]. The con-
ditioning consisted of ﬂudarabine, melphalan and alem-
tuzumab. The probabilities of OS and event-free survival
at 2 years were 63 and 56%, respectively. Post-induction
MRD level was the only factor independently inﬂuencing
the risk of relapse (HR= 4.14).
Source of stem cells
In 2010, the vast majority of alloHSCT procedures are being
performed using peripheral blood as a source of stem cells,
although prospective trials demonstrated increased risk of
chronic graft-versus-host disease (GVHD) after peripheral
blood compared to bone marrow transplantation from either
MSD or URD [53]. In prospective studies comparing both
sources of stem cells, patients with ALL constituted minority,
therefore any speciﬁc conclusions regarding the effect on the
overall outcome could be drawn. Results of a retrospective
analysis by the EBMT suggest a trend towards reduced risk of
relapse for peripheral blood transplants (HR= 0.69, p=
0.06), without signiﬁcant effect on NRM, LFS or OS [1].
It has been demonstrated that the risk of chronic GVHD
may be decreased by the use of anti-thymocyte globulin
(ATG) as a part of conditioning regimen [54–56]. Once again,
prospective, randomized studies addressing this issue were
not speciﬁcally focused on adults with ALL. More recently, a
retrospective analysis has been performed on behalf of the
EBMT, including patients with Ph-negative ALL treated with
either MSD-HSCT or URD-HSCT in CR1 [57]. The use of
ATG was associated with reduced incidence of chronic
GVHD without signiﬁcant impact on LFS or OS. Therefore, it
seems that ATG-based conditioning may be effectively and
safely applied to patients with ALL. Further analyses are
needed to deﬁne optimal dose, brand and timing as well as to
evaluate if the effect is independent of the type of donor.
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HSCT for Ph-negative ALL in CR1: current
clinical practice
Indications for “younger” adults
In order to reﬂect current clinical practice regarding utili-
zation of HSCT for patients with Ph-negative ALL, repre-
sentatives of 11 European study groups were asked to
provide their local guidelines. Data from 11 study groups
have been collected.
As listed in Table 1, the indications for alloHSCT in
CR1 are highly heterogeneous. Similarly, the cut-off age
limit for patients to be considered candidates for intensive
induction–consolidation followed by myeloablative
HSCT varies with a range of 40 years to 65 years. Among
younger patients, positive MRD status is the only risk
factor accepted across all study groups; however, relevant
cut-off levels as well as time-points selected for treatment
decisions are not consistent. Four study groups consider
MRD level to be of clinical relevance both after induction
and consolidation, in four study groups only assessment
during/after consolidation is taken into account, while in
one study group only MRD after two blocks of induction
is used for decision regarding the indications for
alloHSCT. For most of the study groups, post-induction
MRD level of >10−3 of bone marrow nucleated cells is
considered as high-risk feature, while the corresponding
cut-off level after consolidation is usually 10−4 of bone
marrow nucleated cells. Both molecular methods and ﬂow
cytometry are used for MRD assessment in current clin-
ical practice, although the use of PCR-based methods
predominates. Among other potential prognostic factors,
high initial leukocyte count, especially for patients with
B-lineage ALL, as well as adverse cytogenetic/molecular
features are considered for treatment decisions regarding
the use of alloHSCT by the majority of study groups. Two
study groups include adverse immunophenotype, while
single study groups include initial involvement of central
nervous system, age >30 years or poor reduction of bone
marrow blast during induction for risk stratiﬁcation. For
three ALL study groups, MRD level is considered the
only surrogate driving clinical decisions regarding the use
of alloHSCT. AlloHSCT is most frequently scheduled
after the ﬁrst course of consolidation.
Finally, only 4 out of the 11 ALL study groups accept
autoHSCT as a treatment option for younger patients with
Ph-negative ALL in ﬁrst CR. This option is restricted to
patients with low or negative MRD status.
Indications for “older” adults
According to a retrospective analysis by the EBMT,
alloHSCT for ALL patients older than 60 years is associated
with 35% LFS rate at 3 years [58]. In four ALL study
groups, alloHSCT is an option for all “older” patients with
Ph-negative ALL being in CR1 (Table 2). In another four
ALL study groups, the indications are restricted to patients
with poor risk features, in particular poor response at MRD
level. Two study groups do not consider alloHSCT for older
patients with Ph-negative ALL at all, while in one group the
decision depends on a local policy of particular centers.
Three ALL study groups accept autoHSCT as a treatment
option for “older” individuals with Ph-negative ALL and
low or negative MRD status despite lack of evidence to
support this strategy.
Choice of donor
In all study groups, MSD is the preferable donor choice for
patients being candidates for alloHSCT. In all but one study
group, 10/10 matched URD is also acceptable (Table 3). The
choice of alternative donors varies among countries. URD with
single HLA mismatch and haploidentical donors are considered
as preferred or optional by almost all ALL study groups.
However, URD with two HLA mismatches and UCB are
considered as options by four and six study groups,
respectively.
Summary of the position statement
1. AlloHSCT is an effective treatment option to prevent
relapse in adults with Ph-negative ALL.
2. The use of alloHSCT in CR1 is recommended in all
patients with features indicating high risk of relapse,
among which the persistence of MRD is the strongest
predictor. Monitoring of MRD using either molecular
methods or ﬂow cytometry should therefore be manda-
tory. AlloHSCT is recommended in all patients with
persistent MRD. The acceptable level of MRD after
induction is <10−3 of bone marrow cells, while after
consolidation it should be undetectable. Selection of
other factors used for stratiﬁcation (e.g., high initial
leukocyte count, adverse genetics or adverse immuno-
phenotype) should depend on speciﬁc chemotherapy
protocol and experience of particular centers or study
groups.
3. For patients treated with intensiﬁed (pediatric-
inspired) chemotherapy protocols who achieve
MRD-negative status, the use of alloHSCT in CR1
may not be required despite the presence of other
high-risk factors.
4. HLA-identical sibling or matched unrelated donors
are the preferred donors for alloHSCT. Patients with
high risk of relapse lacking HLA-matched donor may
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Table 1 Indications for HSCT in younger adults with Ph-negative ALL
Study group Age
(years)a




CELL (Czechia) <65 At least one:
•MRD ≥10−3 after induction




PCR After 1st cycle of
consolidation
FALL (Finland) <45 At least one:




–No CR after ﬁrst course of
induction
–MRD ≥10−3 on day 79
•T-lineage:
–Bone marrow blast count
≥25% on day 15 and ≥5%
after block A of
consolidation
–MRD ≥10−3 after block B of
consolidation
No PCR and/or FC After 1st cycle of
consolidation
GIMEMA (Italy) <65 At least one:
•MRD positivity after
consolidation

















•No CR after induction I
•MRD ≥10−4 after consolidation
I




<60 At least one:
•MRD ≥10−3 after induction
•MRD ≥10−4 after consolidation
No PCR After consolidation
HOVON (The
Netherlands)
<40 At least one:
•MRD ≥10−4 during/after
consolidation
•No CR after ﬁrst course of
induction
•Adverse cytogenetics
•WBC >30 × 109/L in B-ALL or
WBC >100 × 109/L in T-ALL
No FC After intensiﬁcation 1
PALG (Poland) <55 At least one:
•MRD ≥10−3 after induction
•MRD ≥10−4 during/after
consolidation
•WBC >30 × 109/L in B-ALL or

















•MRD >10-3 after induction
•MRD >10-4 during/after
consolidation
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be offered transplantation from mismatched related
(including haploidentical) donor or unrelated donor
with single HLA allele/antigen disparity. Transplanta-
tion of cord blood is an alternative.
5. TBI-based myeloablative conditioning is the prefer-
able one in young patients. TBI may be combined
with either Cy or etoposide. In centers with limited
access to TBI, chemotherapy-based conditioning
using either i.v. busulfan or thiotepa may be
considered. For elderly patients or patients with
comorbidities, reduced intensity conditioning based
on either TBI or chemotherapy is recommended.
6. Either peripheral blood or bone marrow may be used
as sources of stem cells. In case of peripheral blood
transplants, the use of in vivo T-cell depletion should
be considered in order to reduce the risk of chronic
graft-versus-host disease.
Future perspectives
Results of prospective, randomized studies to prove the
MRD-based strategy are pending. A German study group is
currently running a randomized trial comparing alloHSCT
with consolidation chemotherapy for patients achieving
MRD negativity after induction. Results of this study will
verify prognostic relevance of conventional risk factors. For
patients with MRD persistence, the introduction of mono-
clonal antibodies like bispeciﬁc T-cell engager blinatumo-
mab has been demonstrated to provide a very high rate of
molecular remissions [59, 60]. So far, however, it remains
unclear whether this intervention may allow avoidance of
alloHSCT. Novel agents like inotuzumab ozogamycin
(conjugate of anti-CD22 monoclonal antibody with cali-
cheamicin) used as front-line therapy in combination with
reduced-dose chemotherapy are also postulated to increase
the treatment efﬁcacy [61]. With blinatumomab used as
consolidation, followed by maintenance, the need for
alloHSCT may be limited [62]. This hypothesis requires
veriﬁcation in prospective trial. On the other hand, blina-
tumomab is also being tested as maintenance after
alloHSCT in order to reduce the risk of relapse. Future
studies will probably evaluate the role of chimeric antigen
receptor T cells or natural killer cells as well as check-point
inhibitors for ALL patients in remission. The combination
of above-mentioned options may replace alloHSCT in










RALL (Russia) <55 B-cell ALL, at least one:
•Age >30 years






•T-cell ALL, except for
MLL rearrangement
FC or PCR After consolidation
SVALL (Sweden) <65 At least one:
•Leukemic blast count ≥5% after
induction
•MRD ≥10−3 after consolidation
•Optionally for MLL
rearrangement and hypodiploidy
with low MRD level
No B-cell ALL: FC
T-cell ALL: PCR
After consolidation
UKALL (UK) <40 At least one:
•High initial WBC
•Adverse cytogenetics
•MRD ≥10−3 after two cycles of
induction
No PCR After 2 cycles of induction
MRD minimal residual disease, PCR polimerase chain reaction, FC ﬂow cytometry, ALL acute lymphoblastic leukemia, CR complete remission,
CNS central nervous system, WBC white blood cell
aCut-off age deﬁning eligibility for intensive induction–consolidation chemotherapy and hematopoietic stem cell transplantation with
myeloablative conditioning regimen
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however, these perspectives regard patients with B-lineage
ALL while not T-cell ALL.
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